Entresto
Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients
September 2, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …
Novartis’ Entresto falls short at Phase 3 in heart failure with preserved ejection fraction
July 29, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing …
Novartis’ Entresto tops enalapril in stabilised heart failure patients
November 13, 2018Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma
Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …
Novartis’ Entresto helps preserve kidney function in chronic heart failure patients
April 16, 2018Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in …
Novartis rides out fiscal hardship to beat Q3 forecasts
October 25, 2016Manufacturing and Production, Sales and Marketing Entresto, Gleevec, Novartis
Novartis has beaten its third-quarter sales projections, announcing that new product growth and cost cuts managed to carry the company …
Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study
June 23, 2016Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research
A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
NICE gives green light to Novartis’s heart drug Entresto
April 27, 2016Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients
NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …
Research shows Novartis’s Entresto reduces cardiovascular death and heart failure
April 4, 2016Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent
Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
Novartis’s heart failure drug given final recommendation by NICE
March 21, 2016Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug
The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …
Novartis earns provisional NICE yes for Entresto
December 11, 2015Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure
NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
Novartis and Amgen drugs signed-off by European Commission
November 24, 2015Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto
The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …
Novartis’ new heart failure medicine recommended for EU approval
September 25, 2015Medical Communications, Research and Development Entresto, Novartis, eams, heart failure
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
